DEA's Own Pharmacologist Undercuts Marijuana Rescheduling Order

(PR-inside.com) "Government's Own Scientific Expert Testified Marijuana Failed DEA's Traditional Medical Use Standard, Lacked Reproducible Chemistry, and That HHS Omitted Critical Public Health Findings" stated Duane Boise CEO MMJ International Holdings. WASHINGTON, DC / ACCESS Newswire / July 8, 2026 / One witness may ultimately define the entire DEA marijuana rescheduling proceeding-not because she opposed marijuana legalization, but because she authored the Drug Enforcement Administration's own scientific review. Dr. Luli Akinfiresoye, a pharmacologist in DEA's Drug and Chemical Evaluation Section and author of the agency's 2024 Scientific Data Review, testified under subpoena during the marijuana rescheduling hearing. Her testimony revealed a striking scientific ..

HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership

Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to...

Insilico Medicine Releases Positive Profit Alert for the First Half of 2026

CAMBRIDGE, Mass., July 8, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive profit alert for the six months ended June 30, 2026 ("First Half of...

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo

HANGZHOU, China, SHANGHAI and BOSTON, July 8, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on...

Inspirational Memoir “The Miracle of Eve: Saved by Grace!” Shares a Powerful Story of Faith, Survival, Family, and Hope Through Cancer

In her moving and faith-filled memoir, “The Miracle of Eve: Saved by Grace!,” author Yvonne D. Baku opens her heart to readers with a story that is as vulnerable as it is victorious. What began as a season of unexplained pain, exhaustion, uncertainty, and medical appointments soon became a life-altering journey through a diagnosis of stage IV large B-cell non-Hodgkin's lymphoma — a journey that tested her body, her marriage, her family, her faith, and her understanding of purpose. - - At... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=357370

LumaCare Lasers Partners with Flex to Unlock HSA and FSA Funds for Cold Laser Therapy

Cold laser therapy device manufacturer announces its dual-head LumaCare Duo device is now eligible for purchase using HSA and FSA funds through a new partnership with Flex. The post LumaCare Lasers Partners with Flex to Unlock HSA and FSA Funds for Cold Laser Therapy first appeared on

RipeGlobal and Subscribili Partner to Drive Case Acceptance and Practice Growth Across Dental Organizations

Integration combines clinical education, AI-driven scheduling, and in-office membership infrastructure to close the care gap for uninsured patients, accelerate case acceptance, and unlock chair time for DSOs nationwide AUSTIN, Texas, July 8, 2026 /PRNewswire-PRWeb/ -- RipeGlobal, the...

Gout Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

ESCLC Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Eczema Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

RNA Therapies Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Glioblastoma Pipeline Accelerates as 200+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight